e-learning
resources
Berlin 2001
Sunday 23.09.2001
Updates of asthma therapy in children
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children
D. Bellamy, For the Airmax Preference Investigators Group (Muscliffe, Bournemouth, United Kingdom)
Source:
Annual Congress 2001 - Updates of asthma therapy in children
Session:
Updates of asthma therapy in children
Session type:
Thematic Poster Session
Number:
831
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Bellamy, For the Airmax Preference Investigators Group (Muscliffe, Bournemouth, United Kingdom). Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children. Eur Respir J 2001; 16: Suppl. 31, 831
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Efficacy and safety of salbutamol delivered
via
a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children
Source: Eur Respir J 2002; 20: Suppl. 38, 500s
Year: 2002
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage
versus
a dry powder inhaler in moderate to severe asthmatic patients
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients
Source: International Congress 2016 – Asthma management
Year: 2016
One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler.
Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children
Year: 2008
Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler
Source: International Congress 2019 – Innovations in primary care assessment and management
Year: 2019
Evaluation of acceptability, efficacy and safety of a novel dry powder inhaler in patients with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 70s
Year: 2007
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Young children with asthma treated with budesonide inhalation suspension can successfully be transitioned to once-daily budesonide dry powder inhaler
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007
A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
How does the Novolizer fit into the choice of inhaler?
Source: Annual Congress 2005 - Asthma management - important issues
Year: 2005
Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005
Preference for novel soft mist inhaler over pMDI in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 88s
Year: 2004
Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability
Source: Eur Respir J 2002; 19: 246-251
Year: 2002
Salbutamol delivered via a new multi-dose dry powder inhaler is as safe and efficacious as a pressurised metered dose inhaler in children aged 6-12 years
Source: Eur Respir J 2002; 20: Suppl. 38, 501s
Year: 2002
The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009
Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept